
OLD Category: immuno-oncology
February 18, 2021 / J Immunother Cancer
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
February 15, 2021 / J Clin Invest
PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury
February 15, 2021 / J Immunother Cancer
Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies
February 9, 2021 / Cancer Discov
Non-genetic evolution drives lung adenocarcinoma spatial heterogeneity and progression
February 4, 2021 / Oncoimmunology
Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting
February 4, 2021 / Mol Ther Oncolytics
Oncolytic vaccinia virus induces a novel phenotype of CD8+ effector T cells characterized by high ICOS expression
January 28, 2021 / Cancer Immunol Res
Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance
January 27, 2021 / Front Immunol
Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors
January 25, 2021 / Nat Med
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
January 20, 2021 / Cancers (Basel)
Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells
January 19, 2021 / Front. Oncol.